Gamma Secretase (EC 3.4.23.) - Pipeline Review, H1 2018
Gamma Secretase (EC 3.4.23.) - Pipeline Review, H1 2018
SUMMARY
Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.) - Pipeline Review, H1 2018, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain.
The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.
Gamma secretase is also critical in the related processing of the Notch protein. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 11 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders and Cardiovascular which include indications Alzheimer's Disease, Hearing Disorders, Brain Cancer, Burkitt Lymphoma, Congestive Heart Failure (Heart Failure), Glioblastoma Multiforme (GBM), Leukemias, Medulloblastoma, Metastatic Breast Cancer and Soft Tissue Sarcoma.
Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.) - Pipeline Review, H1 2018, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain.
The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.
Gamma secretase is also critical in the related processing of the Notch protein. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 11 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders and Cardiovascular which include indications Alzheimer's Disease, Hearing Disorders, Brain Cancer, Burkitt Lymphoma, Congestive Heart Failure (Heart Failure), Glioblastoma Multiforme (GBM), Leukemias, Medulloblastoma, Metastatic Breast Cancer and Soft Tissue Sarcoma.
Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
- The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Gamma Secretase (EC 3.4.23.) - Overview
Gamma Secretase (EC 3.4.23.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
SpringWorks Therapeutics LLC
Stemline Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Gamma Secretase (EC 3.4.23.) - Drug Profiles
AS-2715348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-932481 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSI-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-226A1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3056480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nirogacestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit PSEN1 for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma Secretase (EC 3.4.23.) - Dormant Products
Gamma Secretase (EC 3.4.23.) - Discontinued Products
Gamma Secretase (EC 3.4.23.) - Product Development Milestones
Featured News & Press Releases
Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers
Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial
Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer’s Disease
Jun 16, 2014: Prof. G.L. Nicolson and Prof. R.M. Epand join Lipopharma's SAB
Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease
Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimer’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Gamma Secretase (EC 3.4.23.) - Overview
Gamma Secretase (EC 3.4.23.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
SpringWorks Therapeutics LLC
Stemline Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Gamma Secretase (EC 3.4.23.) - Drug Profiles
AS-2715348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-932481 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSI-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-226A1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3056480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-555 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nirogacestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit PSEN1 for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma Secretase (EC 3.4.23.) - Dormant Products
Gamma Secretase (EC 3.4.23.) - Discontinued Products
Gamma Secretase (EC 3.4.23.) - Product Development Milestones
Featured News & Press Releases
Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers
Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial
Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer’s Disease
Jun 16, 2014: Prof. G.L. Nicolson and Prof. R.M. Epand join Lipopharma's SAB
Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease
Jul 21, 2009: Critical Outcome Technologies Inc. Announces the Launch of a Drug Discovery Program for Alzheimer’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Astellas Pharma Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Pipeline by Lipopharma Therapeutics SL, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by NeuroGenetic Pharmaceuticals Inc, H1 2018
Pipeline by SpringWorks Therapeutics LLC, H1 2018
Pipeline by Stemline Therapeutics Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Astellas Pharma Inc, H1 2018
Pipeline by Bristol-Myers Squibb Co, H1 2018
Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Pipeline by Lipopharma Therapeutics SL, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by NeuroGenetic Pharmaceuticals Inc, H1 2018
Pipeline by SpringWorks Therapeutics LLC, H1 2018
Pipeline by Stemline Therapeutics Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Astellas Pharma Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
SpringWorks Therapeutics LLC
Stemline Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Astellas Pharma Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
SpringWorks Therapeutics LLC
Stemline Therapeutics Inc
Takeda Pharmaceutical Co Ltd
